<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106312</url>
  </required_header>
  <id_info>
    <org_study_id>N10DMY</org_study_id>
    <secondary_id>2588</secondary_id>
    <nct_id>NCT02106312</nct_id>
  </id_info>
  <brief_title>Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas</brief_title>
  <acronym>DOREMY</acronym>
  <official_title>Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid
      Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A Bayesian approach is considered for the analysis of this trial. The aim is to provide
           a stopping rule for inefficacy of the new dose.

        -  Two aspects are important to elucidate the mechanism of this treatment: dynamic
           investigations of perfusion and vasculature. Apart from participation to the dose
           reduction paragraphs of this study, patients will be also asked to undergo, at
           clinically relevant dose points, dynamic contrast enhanced (DEC) MRI scans and
           separately tumor biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Pathological description of the percentage pathological responses after reduced RT (radiotherapy) dose from (conventionally) 25 x 2 Gy to 18 x 2 Gy (in the current study)</measure>
    <time_frame>The percentage of pathological responses will be pathologically assessed on the resection specimen; this procedure will take on average 7-10 working days. After surgery, patients will be followed up to 10 years.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myxoid Liposarcoma of Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose reduction of preoperative radiotherapy in MLS</intervention_name>
    <description>A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age above or equal to 18 years

          2. Biopsy proven MLS (including the reciprocal chromosomal translocation
             t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for
             management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of
             oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in
             order to postpone the time interval to next systemic chemotherapy. These patients are
             usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for
             convenience purposes (see paragraph 10 for radiobiological considerations).

          3. ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2

          4. Patients must be able (physically, mentally and socially) to complete a series of RT,
             followed by an observation period of 4-6 weeks and undergo surgery.

          5. Written informed consent

        Exclusion Criteria:

          1. Prior radiotherapy to the target area.

          2. Anticoagulant medication of any kind; especially Ascal®(and derivates), coumarines
             (Sintrom® and Marcoumar®), all heparin and heparin-like formulations. (Note: this
             exclusion criterion only applies for patients consenting to the translational research
             part of the study; patients on anticoagulant medication as described above may take
             part in the dose reduction part of the study, but the repeat biopsies may not be
             taken.)

          3. Pregnancy -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick Haas, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rick Haas, MD,Phd</last_name>
    <phone>+31 20 5129111</phone>
    <email>r.haas@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Scholten, MD,PhD</last_name>
    <phone>+31205129111</phone>
    <email>a.scholten@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>MA 02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Healey-Baldini, MD, PhD</last_name>
      <email>EBALDINI@LROC.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Healey-Baldini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>MA 02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Baldini, MD, PhD</last_name>
      <email>EBALDINI@LROC.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Healey-Baldini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akmal Safwat, MD, PhD</last_name>
      <phone>+4578464420</phone>
      <email>akmal@oncology.au.dk</email>
    </contact>
    <investigator>
      <last_name>Akmal Safwat, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Haas, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>r.haas@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Astrid Scholten, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>a.scholten@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Rick Haas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Balgobind, MD, PhD</last_name>
      <phone>+31 20 566 9111</phone>
      <email>b.v.balgobind@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Brian Balgobind, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan F Ubbels, MD</last_name>
      <phone>+31 50 361 1190</phone>
      <email>j.f.ubbels@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Jan F Ubbels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stijn Krol, MD, PhD</last_name>
      <phone>+31 71 526 9111</phone>
      <email>A.D.G.Krol@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Stijn Krol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet van den Ende, MD. PhD</last_name>
      <phone>+31 88 44 55 666</phone>
      <email>piet.vandenende@maastro.nl</email>
    </contact>
    <investigator>
      <last_name>Piet van den Ende, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud umc</name>
      <address>
        <city>NIjmegen</city>
        <zip>6225GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Braam, MD, PhD</last_name>
      <phone>+31 24 361 45 06</phone>
      <email>p.braam@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Petra Braam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Jebsen, MD, PhD</last_name>
      <phone>+47 05300</phone>
      <email>nina.louise.jebsen@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Nina Jebsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oyvind Bruland, Msc, MD, PhD</last_name>
      <phone>+ 47 22 93 40 00</phone>
      <email>oyvind.bruland@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Oyvind Bruland, Msc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aisha Miah, MCRP, FRCR, PhD</last_name>
      <email>aisha.miah@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Aisha Miah, MCRP, FRCR, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Myxoid liposarcoma</keyword>
  <keyword>Soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

